West Pharmaceutical Services, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.07B | $2.89B | $2.95B | $2.89B | $2.83B | $2.15B | $1.84B | $1.72B |
| Cost of Revenue | $1.97B | $1.89B | $1.82B | $1.75B | $1.66B | $1.38B | $1.23B | $1.17B |
| Gross Profit | $1.10B | $998.5M | $1.13B | $1.14B | $1.18B | $767.8M | $605.7M | $545.4M |
| Gross Margin | 35.9% | 34.5% | 38.3% | 39.4% | 41.5% | 35.8% | 32.9% | 31.8% |
| Operating Expenses | ||||||||
| Research & Development | $74.3M | $69.1M | $68.4M | $58.5M | $52.8M | $46.9M | $38.9M | $40.3M |
| SG&A Expense | $393.6M | $338.5M | $353.4M | $316.9M | $362.8M | $302.0M | $272.7M | $262.9M |
| Operating Income | $584.9M | $569.9M | $676.0M | $734.0M | $752.3M | $406.9M | $296.6M | $240.3M |
| Operating Margin | 19.0% | 19.7% | 22.9% | 25.4% | 26.6% | 19.0% | 16.1% | 14.0% |
| Interest Expense | $15.1M | $16.2M | $9.0M | $7.9M | $8.2M | $8.2M | $8.5M | $8.4M |
| Pretax Income | $600.9M | $585.5M | $698.0M | $679.9M | $748.9M | $401.3M | $291.8M | $240.7M |
| Income Tax Expense | $121.6M | $107.5M | $122.3M | $114.7M | $107.2M | $72.5M | $59.0M | $41.4M |
| Net Income | $493.7M | $492.7M | $593.4M | $585.9M | $661.8M | $346.2M | $241.7M | $206.9M |
| Net Margin | 16.1% | 17.0% | 20.1% | 20.3% | 23.4% | 16.1% | 13.1% | 12.0% |
| EPS (Basic) | $6.83 | $6.75 | $7.98 | $7.87 | $8.89 | $4.68 | $3.27 | $2.80 |
| EPS (Diluted) | $6.79 | $6.69 | $7.88 | $7.73 | $8.67 | $4.57 | $3.21 | $2.74 |
| Shares Outstanding (Basic) | 72.3M | 73.0M | 74.3M | 74.4M | 74.4M | 73.9M | 74.0M | 73.9M |
| Shares Outstanding (Diluted) | 72.7M | 73.7M | 75.3M | 75.8M | 76.3M | 75.8M | 75.4M | 75.4M |
| Dividends Per Share | $0.86 | $0.82 | $0.78 | $0.74 | $0.70 | $0.66 | $0.62 | $0.58 |